Nutra Pharma insider gifts 12M preferred shares

Nutra Pharma Corp (NPHC) insider and ten percent owner Rik J. Deitsch reported a bona fide gift of 12,000,000 shares of Series B Preferred Stock on 2026-08-21, leaving him with 0 Series B Preferred shares reported after the transaction.

Rhea-AI Filing Summary

Nutra Pharma Corp (NPHC) insider and ten percent owner Rik J. Deitsch reported a bona fide gift of 12,000,000 shares of Series B Preferred Stock on 2026-08-21, leaving him with 0 Series B Preferred shares reported after the transaction. He continues to hold 43,298,859 shares of Common Stock directly.

Insider Trade Summary

12,000,000 shares gifted

Gift 2 txns

Insider DEITSCH RIK J

Role 10% Owner

Type	Security	Shares	Price	Value
Gift	Series B Preferred Stock	12,000,000	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Series B Preferred Stock — 0 shares (Direct); Common Stock — 43,298,859 shares (Direct)

Key Figures

Series B Preferred Stock gifted: 12,000,000 shares Series B Preferred Stock held after transaction: 0 shares Common Stock held: 43,298,859 shares +2 more

5 metrics

Series B Preferred Stock gifted 12,000,000 shares Bona fide gift on 2026-08-21

Series B Preferred Stock held after transaction 0 shares Total Series B Preferred shares following gift

Common Stock held 43,298,859 shares Direct Common Stock holdings as of 2026-08-21

Gift transactions 1 transaction Gift disposition count in transaction summary

Gifted shares total 12,000,000 shares Gift shares in transaction summary

Key Terms

Bona fide gift, ten percent owner, Series B Preferred Stock, Form 4

4 terms

Bona fide gift regulatory

"transaction_code_description: "Bona fide gift" for the Series B Preferred"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

ten percent owner regulatory

"reporting person is marked as a ten percent owner"

Series B Preferred Stock financial

"security_title: "Series B Preferred Stock" in the transaction record"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) for transactions in NPHC"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NPHC report for Rik J. Deitsch on this Form 4?

Rik J. Deitsch reported a bona fide gift of 12,000,000 shares of Nutra Pharma Corp Series B Preferred Stock on 2026-08-21, with no price reported for the transfer.

How many Series B Preferred shares of NPHC does Rik J. Deitsch hold after the reported gift?

After the reported transaction, Rik J. Deitsch holds 0 shares of Nutra Pharma Corp Series B Preferred Stock, as indicated by the total shares following transaction field.

How many Nutra Pharma Corp (NPHC) common shares does Rik J. Deitsch own after this Form 4 event?

Rik J. Deitsch is shown as directly holding 43,298,859 shares of Nutra Pharma Corp Common Stock in the holding entry dated 2026-08-21.

Was the NPHC insider transaction a buy or a sell?

The NPHC insider transaction was reported as a disposition via bona fide gift (code G), not a market purchase or sale, for 12,000,000 Series B Preferred shares.

Did the NPHC Form 4 indicate use of a Rule 10b5-1 trading plan?

No. The Form 4 data indicates the Rule 10b5-1 checkbox is false, meaning the filer did not affirm that the reported transactions were made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 03:44 PM EDT Accepted by SEC EDGAR 09/01/2026 - 03:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEITSCH RIK J

(Last) (First) (Middle)

7915 NW 111TH WAY

(Street)

PARKLAND FLORIDA 33076

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NUTRA PHARMA CORP [ NPHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Series B Preferred Stock	08/21/2026		G		12,000,000	D	$0	0	D
Common Stock								43,298,859	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Rik J Deitsch	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)